CD276 and medulloblastoma: We now show that anti-B7H3 monoclonal antibody omburtamab can be safely used for cRIT even in patients who had previously received high doses of chemotherapy and radiotherapy to extensive fields, as is the case for patients with relapsed CNS neuroblastoma or medulloblastoma post craniospinal irradiation [13].